Document is current
Any future updates will be listed below
-
Authors
de Castro, Luiz Claudio Gonçalves https://orcid.org/0000-0002-9166-1837
de Carvalho, Julienne Angela Ramires
Alves, Crésio de Aragão Dantas
Félix, Têmis Maria
Bordallo, Ana Paula
Arrais, Ricardo Fernando
Ribeiro, Erlane Marques
de Medeiros, Paula Frassinetti Vasconcelos
Linden Nader, Ivana van der
Garcia, Lena Stilianidi
Baratela, Wagner Antonio da Rosa
Simoni, Genoir
Colares Neto, Guido de Paula
Fock, Rodrigo Ambrosio
Cominato, Louise
Collett-Solberg, Paulo Ferrez
de Souza Rio, Kênia Maria
Yamin, Juliana Lopes
Llerena Jr, Juan Clinton
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical (BioMarin Pharmaceutical)
- License Information
-
More Information
Article History
Received: 18 February 2026
Accepted: 21 July 2026
First Online: 6 August 2026
Declarations
Ethics approval and consent to participate: Not applicable.
Consent for publication: Not applicable.
Competing interests: All authors received support from BioMarin to participate in this consensus. LCGC, APB, LSG, EMR, GPCN, RAF and JCLJ report receiving speaker honoraria from BioMarin for lectures at scientific events. PACS received travel grants and lecture fees from BioMarin, Novo Nordisk, Pfizer, and Sandoz. JLY is the president of a patient association group, which receives sponsorship from a pharmaceutical company for events and institutional activities. The authors declare that BioMarin had no role in the study design, the Delphi voting process, the analysis and interpretation of data, or the final formulation of the recommendations.
